No Image

Jushi Holdings Inc. Announces Closing Of Sale Of Its Minority Stake In Gloucester Street Capital For Cash And Equity

BOCA RATON, Fla., Oct. 10, 2019 /PRNewswire/ — Jushi Holdings Inc. (“Jushi” or the “Company”) (NEO: JUSH.B) (OTCQX: JUSHF), a globally-focused, multi-state cannabis and hemp operator, today announced the closing of the sale of its 16.5% ownership interest in Gloucester Street Capital (“Gloucester”), the parent company of Valley Agriceuticals and owner of one of ten New York licensed medical cannabis operators. Jushi previously purchased its 16.5% interest in Gloucester in February 2018 for US$5 million in cash. The sale is part of the Cresco Labs Inc.’s (CSE: CL) (OTCQX: CRLBF) acquisition of Gloucester.


No Image

Industry Leader Aromafloria Introduces Cannafloria Essentials

HUNTINGTON STATION, N.Y., Oct. 10, 2019 /PRNewswire/ — Aromafloria, the prolific Long Island based manufacturer of bath and body products, announces the launch of Cannafloria Essentials, a luxurious new collection of aromatherapy body, mind and skincare products that uniquely harnesses the benefits of cannabis terpenes, helping consumers take self-care to a whole new level. Cannafloria’s mission is to help navigate stress and empower users to feel good in the moment by combining the power of science, beauty and wellness. The Cannafloria Essentials line features nine forms of relief including inhalation beads, roll-ons, all-natural body lotions, hand creams, bath fizzes, sugar scrubs, bath milks, mood mists and shower gels with CBD body products slated for launch in late 2019 and CBD facial skincare coming in 2020.


No Image

kJ Labs Says Flavor Bans Will Fail

IRVINE, Calif., Oct. 10, 2019 /PRNewswire/ — kJ Laboratories, prominent e-cigarette manufacturer of The Jones(TM) pods and The Jones(TM) Quick fix disposables ( www.thejonespods.com ), announce our support for common-sense regulation.


No Image

Cultivators Manipulate Cannabis Plants to Offer Consumers Diverse Products

NEW YORK, Oct. 10, 2019 /PRNewswire/ — Innovative cannabis cultivators have created thousands of unique strains through complex breeding processes and technical growing methods. Generally, the growing process of a cannabis plant heavily determines the cannabinoid content within the strain. Cannabinoids, like tetrahydrocannabinol (THC) or cannabidiol (CBD), are chemical substances within strains that connect to the cannabinoid receptors within the consumer’s body and brain, causing a stimulating effect. To note, THC and CBD impart widely different effects on consumers because of their genetic makeup. Specifically, THC derives from the marijuana plant of the cannabis family, which is commonly known to cause mind-altering effects for its consumers. On the other hand, CBD stems from the hemp plant within the cannabis family and unlike THC, does not cause any psychoactive effects. Moreover, the growing process also determines the terpene development of cannabis plants, helping to dictate the flavor and aroma a strain gives off, similar to how an orange radiates its citrusy smell and taste. The most common terpene found in cannabis plants is myrcene, which is also found within mangoes. Myrcene is responsible for giving a strain’s distinctive smell that most people acknowledge. Additionally, myrcene is known to provide several therapeutic benefits as well as anti-inflammatory properties. But perhaps most importantly, myrcene can also determine whether a strain is indica or sativa-dominant. Generally, plants that contain more than 0.5% myrcene are said to be indica. The common understanding is that sativa offers consumer cerebral-altering head highs, while indica strains provide more of a body-dominant effect. However, it is difficult to consistently classify many strains as either exclusively indica or sativa because of rampant crossbreeding. For instance, many cultivators tend to crossbreed sativa and indica strains to purposely select specific cannabinoids and terpenes within each strain and create a unique, desirable mix. In fact, breeders can mix and match between well over hundreds of different strains, creating an endless array of hybrid options. Overall, the ability to create hybrid strains from already pre-existing strains opens a whole new market for the broader cannabis industry. And according to data compiled by Ameri Research, the global legal marijuana market was valued at USD 14.3 Billion in 2016. By 2024, legal marijuana global sales are projected to reach USD 63.5 Billion while exhibiting a CAGR of 21.1% from 2017 to 2024. Smart Decision, Inc. (OTC: SDEC), Charlotte’s Web Holdings, Inc. (OTC: CWBHF) (TSX: CWEB), Origin House (OTC: ORHOF) (CSE: OH), Liberty Health Sciences Inc. (OTC: LHSIF) (CSE: LHS), Medmen Enterprises Inc. (OTC: MMNFF) (CSE: MMEN)


No Image

Vapen MJ Appoints ASU Professor Jeffery L. Yarger, Ph.D. to Advisory Board

VANCOUVER, Oct. 10, 2019 /PRNewswire/ – Vapen MJ (OTCQX:VAPNF; CSE:VAPN) (“Vapen MJ”) a fully integrated manufacturer and distributor of cannabis THC and hemp CBD products under the Vapen Brand, leveraging core expertise in extraction and marketing to build wholesale distribution through revenue and profit sharing partnerships, announced today that Jeffery L. Yarger, Ph.D. has been appointed to Vapen MJ’s advisory board.


No Image

Regulators Strive to Limit Illicit Cannabis Trade as the Industry Continues its Expansion

NEW YORK, Oct. 10, 2019 /PRNewswire/ — Most regions around the world allow young adults at the age of 18 to enjoy or purchase their own alcohol and tobacco. However, the U.S. has strictly enforced that adults must be 21 years old or older in order to purchase alcohol. Meanwhile, some parts of the U.S. have also implemented a mandated age of 21 years or older to purchase tobacco. The U.S. government strongly believed that if the minimum age requirement was raised to 21 it would reduce the number of young adults drinking and smoking. However, Mike Males, a Senior Researcher for San Francisco’s Center on Juvenile and Criminal Justice, highlighted that changing the age limit has little to no effect in the reduction of underage users. Additionally, teenagers are more likely to obtain their supply from an illegal source and consequently, teenagers are more likely to drink or smoke in excess. Similarly, as the legal cannabis market begins to take off, lawmakers are approaching the industry with caution. In U.S. states where cannabis is legal for adult-use, only adults 21 years old and over are allowed to purchase any cannabis-based products. On the other hand, Canada allows consumers 18 years old and older (19 years old in some provinces) to purchase cannabis-based products. The age difference between the two countries allows Canada to minimize the illicit trade market. Similarly, the United States setting the legal age at 18 years old would add a whole new demographic of young adults to the market, expanding the market penetration even further. And according to data compiled by Imarc Group, the North American legal cannabis market is expected to reach USD 35 Billion by 2023 from USD 8 Billion in 2017. Additionally, the market is expected to register a healthy CAGR of 28% throughout the forecast period. Global Payout, Inc. (OTC: GOHE), The Supreme Cannabis Company, Inc. (OTC: SPRWF) (TSX: FIRE), Emerald Health Therapeutics Inc. (OTC: EMHTF) (TSX-V: EMH), 22nd Century Group, Inc. (NYSE: XXII), Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI)


No Image

From Cartier to Cannabis: Lowell Herb Co. Welcomes Stacey Hallerman As Chief Administrative Officer & General Counsel

LOS ANGELES, Oct. 10, 2019 /PRNewswire/ — Lowell Herb Co., one of the fastest growing cannabis companies, today announced the appointment of Stacey Hallerman to the newly created position of Chief Administrative Officer and General Counsel. In this critical role, she will lead the day-to-day internal operations of the company and oversee the legal, compliance and human resources functions.


No Image

Medical Marijuana, Inc. Subsidiary Kannaway® Announces Launch of New Website and Back Office for Japan Division

SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (“the Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, today announced that its subsidiary Kannaway® has launched a new website and back office available in Japanese catered to servicing the expansion into Japan and Asia.


No Image

CBD Use Grows as Nations Relax Restrictions

NEW YORK, Oct. 10, 2019 /PRNewswire/ — The U.S. Drug Enforcement Agency recently announced plans to expand cannabis research after a prolonged delay. The DEA said it hopes to receive a variety of compelling research about marijuana after the agency delisted CBD, or cannabidiol, from the Schedule 1 list last year. It is important to note, however, that the cannabis plant itself is still a Schedule 1 drug. CBD, meanwhile, is a compound found within the hemp plant, which itself falls within the cannabis family. Previously, cannabis research was heavily limited as there were only a few researchers who were allowed to cultivate and provide cannabis for medical purposes. However, over the past several years, many researchers have delivered uplifting results from clinical trials that proved cannabis is a reliable and effective medical treatment. Now, medical cannabis is predominantly being used to alleviate symptoms associated with afflictions such as chronic pain, cancer, and epilepsy. The positive data has even led many U.S. states to legalize medical cannabis. And as of 2019, there were 33 states and the District of Columbia that have already moved to legalize medical cannabis. In general, the U.S. was one of the earliest adopters of medical cannabis when California first legalized medical use in 1996. Since then, a number of countries such as Australia, Colombia, Germany, France, Spain, Thailand, and South Korea have all been influenced by the data and have also moved to legalize medical cannabis. As a result, the global legal marijuana market is expected to reach USD 146.4 Billion by 2025 while registering a CAGR of 34.6%, according to data compiled by Grand View Research. Newleaf Brands Inc. (OTC: NLBIF) (CSE: NLB), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Pyxus International Inc. (NYSE: PYX), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Cronos Group Inc. (NASDAQ: CRON)


No Image

The Psilocybin Mushroom Story Could be the Next Big Investment Boom

PALM BEACH, Florida, Oct. 10, 2019 /PRNewswire/ — As the cannabis market booms, another drug may soon follow in its footsteps — psilocybin mushrooms. Already, we’re seeing a groundswell of interest. In fact, activists in California are working on getting its decriminalization added to the 2020 ballot. The proposed amendment – called the California Psilocybin Decriminalization Initiative — would revise state drug laws to decriminalize the “personal possession, storage, use, cultivation, manufacturing, distribution in personal possession amounts, according to Marijuana Moment. Better, the U.S. FDA already granted ‘breakthrough status’ to COMPASS Pathways’ psilocybin-assisted therapy in October 2018, which allows the FDA assist in the development of a promising drug to treat serious illnesses. In addition, researchers at New York University found psilocybin mushrooms caused a ‘rapid and sustained’ reduction in anxiety and depression in patients with cancer,” as reported by the Financial Post. As excitement builds, it’s opening a range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), GW Pharmaceuticals (NASDAQ:GWPH), Tilray Inc. (NASDAQ:TLRY), Aphria Inc. (NYSE:APHA) (TSX:APHA), and The Green Organic Dutchman (TSX:TGOD)(OTCQX:TGODF).